← Eichor
Condition: Aml Adult Recurrent Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Aml Adult Recurrent

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 2 location(s) · iCell Gene Therapeutics · NCT07668557Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Pacylex Pharmaceuticals · NCT06613217CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in
Phase 2 · 20 location(s) · French Innovative Leukemia Organisation · NCT06022003A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Phase 1 · 3 location(s) · Cullgen (Shanghai),Inc · NCT07347171Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysp
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02115295A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05748197Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients Wi
Phase 1 · 1 location(s) · BlueSphere Bio, Inc · NCT07566585CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Phase 2 · 1 location(s) · University of Maryland, Baltimore · NCT04050280Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Phase 1 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT03826992Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
NA · 20 location(s) · Massachusetts General Hospital · NCT05237258Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT06802315Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT053058593'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Venetoclax Basket Trial for High Risk Hematologic Malignancies
Phase 1 · 5 location(s) · Andrew E. Place, MD · NCT05292664A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML
NA · 1 location(s) · Ruijin Hospital · NCT06329999Novel Digital Application for Patients With Acute Leukemia
NA · 3 location(s) · Massachusetts General Hospital · NCT06472128HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Pa
Phase 1/Phase 2 · 34 location(s) · Aptose Biosciences Inc. · NCT03850574CLL-1 CAR-NK Cells for Relapsed/Refractory AML
Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06307054Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT
Phase 1/Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07591649Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19
Phase 1 · 1 location(s) · University Hospital, Lille · NCT06649227Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06420063CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05672147
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.